UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)  April 3, 2007

 

VIVUS, INC.

(Exact name of registrant as specified in its charter)

 

 

1172 CASTRO STREET

MOUNTAIN VIEW, CA 94040

(Address of principal executive offices, including zip code)

 

(650) 934-5200

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 8.01.  Other Events

On April 3, 2007, VIVUS, Inc. issued a press release titled “VIVUS to Present at the CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference.”  A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference into any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01.  Financial Statements and Exhibits

(d)  Exhibits.

 

Exhibit No.		Description
99.1		Press Release dated April 3, 2007

 

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

				VIVUS, INC.
		By:		/s/ Timothy E. Morris
				Timothy E. Morris Vice President, Finance and Chief Financial Officer

 

Date:  April 3, 2007

---

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Press Release dated April 3, 2007

 

Exhibit 99.1

CONTACT:

VIVUS, Inc.	Trout Group
Timothy E. Morris	Ian Clements(SF)/Brian Korb(NYC)
Chief Financial Officer	415-392-3385 (SF)
650-934-5200	646-378-2923 (NYC)

 

FOR IMMEDIATE RELEASE

VIVUS to Present at the CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference

MOUNTAIN VIEW, Calif., April 3, 2007 - VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity and sexual health, today announced that the company is scheduled to present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on Wednesday, April 11, 2007 at 3:40p.m. (ET) at the Millennium Broadway Hotel in New York City.  Timothy E. Morris, VIVUS’ vice president finance and chief financial officer, is scheduled to provide a corporate overview of the company and its clinical development programs.  Mr. Morris will also discuss the company’s latest agreement for the rights to EvaMist.

A live audio webcast will be available at the VIVUS website at http://www.vivus.com.  A replay of the presentation will be available for 30 days following the event.

About VIVUS

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. VIVUS has three products that are positioned to enter Phase 3 clinical trials, and one product currently under NDA review by the FDA. The investigational pipeline includes: Qnexa(TM), for which a Phase 2 study has been completed for the treatment of obesity; Testosterone MDTS(R), for which a Phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); EvaMist(TM), for which a Phase 3 study has been completed and an NDA submitted for the treatment of menopausal symptoms; and avanafil, for which a Phase 2 study has been completed for the treatment of erectile dysfunction (ED). MUSE(R) is approved and currently on the market for the treatment of ED. For more information on clinical trials and products, please visit the company’s web site at www.vivus.com.

###